No results for ‘’
Transgene Biotek Ltd
₹2.77
(3.15%)
Sun, 13 Sept 2026, 11:19 am
Health Technology
Biotechnology
24.5KTransgene Biotek Share Price Live Chart
1 Day
(3.15%)
No Result Found
Summary
Market Cap (in Cr)
23.87
Net Profit (in Cr)
-0.68
P/B
2.54
Sector P/E
58.57
P/E
0
EV/EBITDA
0
Debt/Equity (Industry)
0.63
Interest Cover (Industry)
1.51
ROCE (Industry)
0.04
RONW (Industry)
0.02
ROE
0
ROCE
0
Debt/Equity
1.38
EPS (TTM)
0
Dividend Yield
0
Book Value
1.22
Interest Cover
-1.83
Analysis
all
- Transgene Biotek's level of debt (31.6%) compared to net worth is satisfactory (less than 40%).
- Low level of unsold assets.
- Transgene Biotek is good value based on assets compared to the IN Biotechs industry average.
- 526139 outperformed the Market in India which returned -14.5% over the past year.
- BSE:526139 is up 45.2% outperforming the Biotechs industry which returned 18.2% over the past month.
- Unable to evaluate Transgene Biotek's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Transgene Biotek's dividend against the top 25% market benchmark as the company has not reported any payouts.
- Transgene Biotek's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
- Transgene Biotek has less than a year of cash runway if free cash flow continues to grow at historical rates of 22% each year.
- Transgene Biotek has less than a year of cash runway based on current free cash flow.
Shareholding
| Shareholders | MAR 2026 | DEC 2025 | SEPT 2025 | JUN 2025 | MAR 2025 |
|---|---|---|---|---|---|
| Promoters | 23.64 | 23.64 | 23.64 | 23.64 | 23.64 |
| FII | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 |
| Public | 76.36 | 76.36 | 76.36 | 76.36 | 76.36 |
| Government | 0 | 0 | 0 | 0 | 0 |
Technical Analysis
Support and Resistance
| Type | R3 | R2 | R1 | PP | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | 4.32 | 3.64 | 3.26 | 2.96 | 2.58 | 2.28 | 1.60 |
| Fibonacci | 3.64 | 3.38 | 3.22 | 2.96 | 2.70 | 2.54 | 2.28 |
| Camarilla | 3.06 | 2.99 | 2.93 | 2.96 | 2.81 | 2.75 | 2.68 |
Pivots Level: Classic
R3
+1.36
4.32
R2
+0.68
3.64
R1
+0.29
3.26
S1
-0.39
2.58
S2
-0.68
2.28
S3
-1.36
1.60
Moving Average
Period
Value
10-EMA
2.78
20-EMA
2.81
30-EMA
2.84
50-EMA
2.88
100-EMA
2.91
200-EMA
3.09
Corporate Actions
| Announcement Date | Purpose | Action | Ex Date |
|---|---|---|---|
| 29 May 2026 | board-meetings | Accounts, Quarterly Results | |
| 13 Feb 2026 | board-meetings | Quarterly Results | |
| 08 Dec 2025 | egm | ||
| 14 Nov 2025 | agm | ||
| 14 Nov 2025 | board-meetings | Quarterly Results, Half Yearly Results | |
| 12 Nov 2024 | agm | ||
| 14 Nov 2023 | agm | ||
| 13 Aug 2022 | agm | ||
| 14 Aug 2021 | agm |
Peer Comparison
Transgene Biotek Ltd
Fortis Healthcare Ltd
Apollo Hospitals Enterprise Ltd
Aster DM Healthcare Ltd
Max Healthcare Institute Ltd
Narayana Hrudayalaya Ltd
Transgene Biotek Ltd About
Transgene Biotek is an Indian public biotech firm, established in 1990, focused on R&D for vaccines, oncology, biogenerics, and novel drug delivery (oral/nasal proteins/peptides) for unmet needs, exporting to various global markets and developing treatments for cancer, auto-immune issues, etc
Industry
Miscellaneous
Founded
1990
Headquarters
CEO
K Koteswara Rao
Employees
Contact
Website
http://www.transgenebiotek.com
info@transgenebiotek.com
Phone
Location
Plot No 69 & 70 IDA Bollaram, , Sangareddy, Telangana, 502325
Transgene Biotek Ltd Company History
| Year | History |
|---|---|
| 1993 |
|
| 2011 |
|
| 2012 |
|
| 2013 |
|
| 2014 |
|
Deals
| Client Name | Deal Type | Order Side | QTY | Avg Price | Date |
|---|---|---|---|---|---|
| SAHASRAR CAPITAL PRIVATE LIMITED | bulk | Buy | 371570 | 7.83 | 01 Dec 2023 |
| GEETANJALI INVESTMENTS | bulk | Sell | 896281 | 8.16 | 01 Dec 2023 |
| MAYUR VIJAY PATWA | bulk | Buy | 401000 | 8.19 | 01 Dec 2023 |
| GEETANJALI INVESTMENTS | bulk | Sell | 716159 | 9.1 | 24 Nov 2023 |
| SAHASRAR CAPITAL PRIVATE LIMITED | bulk | Buy | 350000 | 9.12 | 24 Nov 2023 |
| GEETANJALI INVESTMENTS | bulk | Sell | 447728 | 8.7 | 23 Nov 2023 |
| SH AS ENTERPRISES LLP | bulk | Buy | 400000 | 3.36 | 27 Mar 2014 |
| GEETANJALI INVESTMENTS | bulk | Buy | 1785488 | 2.02 | 19 Jun 2013 |
| DIPESH NALINBHAI DAVE | bulk | Buy | 1000000 | 2.03 | 19 Jun 2013 |
| GEETANJALI INVESTMENTS | bulk | Buy | 3445350 | 1.95 | 18 Jun 2013 |
Frequently Asked Questions
1.What is the stock price of Transgene Biotek Ltd?
As of 13/09/2026 at 4:49 PM, Transgene Biotek Ltd shares are trading at ₹2.77.
2.What is the market cap. of Transgene Biotek Ltd?
As of 13/09/2026, the market capitalization of Transgene Biotek Ltd is ₹18.81 crore.
3.When was Transgene Biotek Ltd founded?
Transgene Biotek Ltd was founded in 1990.
4.How can I buy shares of Transgene Biotek Ltd?
You can buy shares of Transgene Biotek Ltd through Pocketful. Simply open a Demat account, complete your KYC, add funds, and place a buy order.
5.Does Transgene Biotek Ltd pay dividends?
No, Transgene Biotek Ltd does not pay dividends to eligible shareholders currently.
6.What are the latest financial results of Transgene Biotek Ltd?
For January,2024, Transgene Biotek Ltd reported revenue of ₹0.26 crore and a net profit of ₹-0.68 crore.
7.Who is the CEO of Transgene Biotek Ltd?
The CEO of Transgene Biotek Ltd is K Koteswara Rao.